Home
Search
Study Topics
Glossary
|
Descriptive Information Fields | |||||||||
---|---|---|---|---|---|---|---|---|---|
Brief Title † | Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis | ||||||||
Official Title † | Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: a Randomized, Double-Blind, Controlled Study | ||||||||
Brief Summary | Idiopathic pulmonary fibrosis (IPF) is a diffuse lung disease, associated with the histological appearance of usual interstitial pneumonia (UIP), with an inexorably deteriorating clinical course. Prognosis is poor, reported median survival is less than 3 years. The prevalence is estimated as being 3 to 10 per 100.000 in different Western populations. To date, no pharmacological therapy has been proven to alter or reverse the pathogenic process of IPF. Most treatments trials have been observational case series of small patient populations and very few have been randomized, prospective and placebo-controlled. Two recent Cochrane reviews investigated the role of corticosteroids and other immunomodulatory agents and concluded that there is no evidence for their use in IPF. Most current therapies are targeted to suppress the inflammatory component of the disease, based on the theory that it would be chronic alveolar inflammation which leads to parenchymal remodeling and fibrosis. Recently, a hypothesis that has gained acceptance suggests that fibrosis may result directly from alveolar injury, promoting an abnormal fibrogenic repair mediated by fibroblasts and myofibroblasts. One of the cytotoxic agents most widely used and better tolerated in the management of IPF is azathioprine. Based upon limited data available and from a single small high quality randomized controlled trial (RCT), this drug appears to confer, given in conjunction with prednisone, a marginal long term survival advantage. Since this combination therapy is associated serious adverse effect, we planned to design a trial of low dose corticosteroid and azathioprine versus placebo in management of IPF, evaluating progression-free survival. Our study hypothesis is: Combined therapy with azathioprine and corticosteroids improves progression-free survival in patients with the diagnosis of IPF. |
||||||||
Detailed Description | We will evaluate all adult patients consecutively referred from March 2005 to the Instituto Nacional del Tórax (Thorax National Institute), Santiago, Chile for diagnostic evaluation of Pulmonary Fibrosis. The routine evaluation will include, when indicated, the following steps:
Those patients with IPF diagnosed on the basis of clinical and radiographic criteria alone according to the ATS/ERS consensus committee (3), and/or with a biopsy proven histological pattern of UIP, will be selected to the randomization process, after they have signed the written informed consent. |
||||||||
Study Phase | |||||||||
Study Type † | Interventional | ||||||||
Study Design † | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study | ||||||||
Primary Outcome Measure † | Progression-free survival, defined as free of death or a decrease from baseline in the FVC of at least 10%. [ Time Frame: 2 years ] | ||||||||
Secondary Outcome Measure † | Number of Acute Exacerbations of IPF. [ Time Frame: 2 years ] Health Related Quality of life, measured with the Chronic Questionnaire (CRQ). [ Time Frame: 2 years ] PO2 at rest and at exercise from baseline. [ Time Frame: 2 years ] P(A-a)O2 at rest and at exercise from baseline. [ Time Frame: 2 years ] Predicted FEV1 from baseline. [ Time Frame: 2 years ] Forced expiratory volume in one second (FEV1) to FVC from baseline. [ Time Frame: 2 years ] Plethysmographic lung volumes from baseline. [ Time Frame: 2 years ] Diffusion capacity for carbon monoxide (DLco) from baseline. [ Time Frame: 2 years ] Six-Minute Walk test, from baseline: resting and 6 minute SpO2, presence or absence of desaturation to 88% or lower at the end of the six minute walk, walked distance d. Pre and post modified Borg dyspnea scores [ Time Frame: 2 years ] Scoring of extent of lung fibrosis on HRCT, according to two independent chest radiologists, form baseline. [ Time Frame: 2 years ] Number and severity of adverse effects. [ Time Frame: 2 years ] Number of protocol drop outs. [ Time Frame: 2 years ] |
||||||||
Condition † | Idiopathic Pulmonary Fibrosis | ||||||||
Intervention † | Drug: Placebo Drug: AZAPRED |
||||||||
MEDLINE PMIDs | |||||||||
Links | |||||||||
Recruitment Information Fields | |||||||||
Recruitment Status † | Recruiting | ||||||||
Enrollment † | 100 | ||||||||
Start Date † | May 2005 | ||||||||
Completion Date | December 2008 | ||||||||
Eligibility Criteria † | Inclusion Criteria:
Exclusion Criteria:
|
||||||||
Gender | Both | ||||||||
Ages | 45 Years to 79 Years | ||||||||
Accepts Healthy Volunteers | No | ||||||||
Contacts †† |
|
||||||||
Location Countries † | Chile | ||||||||
Administrative Information Fields | |||||||||
NCT ID † | NCT00518310 | ||||||||
Organization ID | 10351 | ||||||||
Secondary IDs †† | |||||||||
Study Sponsor † | Thorax National Institute | ||||||||
Collaborators †† | Sociedad Chilena de Enfermedades Respiratorias Servicio de Salud Metropolitano Oriente, Ministerio de Salud de Chile |
||||||||
Investigators † |
|
||||||||
Information Provided By | Thorax National Institute | ||||||||
Verification Date | August 2007 | ||||||||
First Received Date † | August 16, 2007 | ||||||||
Last Updated Date | August 16, 2007 |